FINANCIAL STATEMENTS ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2007 125 NOTES TO THE FINANCIAL STATEMENTS CONTINUED 3 FINANCE INCOME AND EXPENSE 2007 2006 2005 $m $m $m Finance income Returns on fixed deposits and equity securities 52 29 15 Returns on short-term deposits 298 330 197 Expected return on post-employment defined benefit plan assets 573 518 448 Fair value gains on debt, interest rate swaps and investments 36 11 Net exchange gains 5 959 888 665 Finance expense Interest on debt and commercial paper 513 59 42 Interest on overdrafts and other financing costs 9 13 19 Interest on post-employment defined benefit plan liabilities 539 475 433 Fair value charges on debt, interest rate swaps and investments 6 6 Net exchange losses 3 14 1,070 561 500 Net finance expense income 111 327 165 The amount of exchange gains and losses recognised in income, other than those arising on financial instruments measured at fair value through profit or loss in accordance with IAS 39 see Note 17, is losses of $3m 2006 $14m losses, 2005 $5m gains.
4 TAXATION Taxation recognised in the income statement is as follows: 2007 2006 2005 $m $m $m Current tax expense Current year 1,890 2,431 1,747 Adjustment for prior years 261 270 112 2,151 2,701 1,859 Deferred tax expense Origination and reversal of temporary differences 379 81 165 Adjustment to prior years 174 140 81 Total taxation expense in the income statement 2,356 2,480 1,943 Taxation has been provided at current rates on the profits earned for the periods covered by the Group Financial Statements.
The 2007, 2006 and 2005 prior period current tax adjustments relate mainly to provision to return adjustments, an increase in provisions in respect of a number of transfer pricing audits and double tax relief.
The 2007, 2006 and 2005 prior year deferred tax credits relate to provision to return adjustments and the recognition of previously unrecognised deferred tax assets.
To the extent that dividends remitted from overseas subsidiaries, joint ventures and associates are expected to result in additional taxes, appropriate amounts have been provided for.
No deferred tax has been provided for unremitted earnings of Group companies overseas as these are considered permanently employed in the businesses of these companies.
Unremitted earnings may be liable to overseas taxes and or UK taxation after allowing for double taxation relief if they were to be distributed as dividends.
The aggregate amount of temporary differences associated with investments in subsidiaries, branches and associates, and interests in joint ventures for which deferred tax liabilities have not been recognised totalled approximately $12,639m at 31 December 2007 2006 $13,291m, 2005 $13,649m.
FINANCIAL STATEMENTS 126 ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2007 NOTES TO THE FINANCIAL STATEMENTS CONTINUED 4 TAXATION CONTINUED Consolidated statement of recognised income and expense The current tax credit on consolidation exchange adjustments taken to reserves amounted to $32m in 2007 2006 credit of $62m, 2005 charge of $46m.
The current tax credit on share-based payments amounted to $1m 2006 $36m, 2005 $nil.
The deferred tax credit taken to reserves amounted to $nil in 2007 2006 $39m, 2005 $21m.
Factors affecting future tax charges As a group involved in worldwide operations, AstraZeneca is subject to several factors that may affect future tax charges, principally the levels and mix of profitability in different jurisdictions, transfer pricing regulations and tax rates imposed.
A number of material items currently under audit and negotiation are set out in detail in Note 27.
Tax reconciliation to UK statutory rate The table shown below reconciles the UK statutory tax charge to the Groups total tax charge.
2007 2006 2005 $m $m $m Profit before tax 7,983 8,543 6,667 Notional taxation charge at UK corporation tax rate of 30% 30% for 2006, 30% for 2005 2,395 2,563 2,000 Differences in effective overseas tax rates 105 156 128 1 Deferred tax income relating to reduction in UK and other tax rates 57 Unrecognised deferred tax asset 1 6 25 Items not deductible for tax purposes 70 58 117 Items not chargeable for tax purposes 33 109 102 Adjustments in respect of prior periods 87 130 31 Total tax charge for the year 2,356 2,480 1,943 1 The majority of this item relates to the reduction in the UK statutory corporation tax rate from 30% to 28% effective from 1 April 2008.
Deferred tax Deferred tax assets and liabilities and the movements during the year, before offset of balances within countries, are as follows: Losses Pension Inter and tax Property, and postcompany Deferred credits plant and Intangible retirement inventory Untaxed Accrued Share capital carried 1 equipment assets bene ts transfers reserves expenses schemes gains forward Other T otal $m $m $m $m $m $m $m $m $m $m $m Deferred tax assets at 1 January 2006 119 461 821 200 82 12 1,695 Deferred tax liabilities at 1 January 2006 842 200 492 94 62 1,690 Net deferred tax balance at 1 January 2006 723 200 461 821 492 200 82 94 50 5 At 1 January 2006 723 200 461 821 492 200 82 94 50 5 Income statement 63 175 54 18 315 112 26 8 57 23 221 Statement of recognised income and expense 35 4 39 2 Acquisition of subsidiary undertaking 454 454 Exchange 133 10 54 14 74 11 1 13 150 Net deferred tax balance at 31 December 2006 793 489 604 853 881 323 113 99 57 27 339 Deferred tax assets at 31 December 2006 37 2 604 853 323 113 57 28 2,017 Deferred tax liabilities at 31 December 2006 830 491 881 99 55 2,356 Net deferred tax balance at 31 December 2006 793 489 604 853 881 323 113 99 57 27 339 1 Untaxed reserves relate to taxable pro ts where the tax liability is deferred to later periods.
2 The deferred tax liability of $454m relates to the acquisitions of KuDOS Pharmaceuticals Limited and Cambridge Antibody Technology Group plc Note 24.
During the course of 2006 the Humira royalty stream was sold resulting in a release of the deferred tax liability of $198m recognised on acquisition.
